Citation tools
"Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results Up to 1-Year from Two Phase 3 Studies." The Journal of Rheumatology
53.Suppl 1
(2026):
86.
Web. 10 Aug. 2026.

